Cleveland Clinic nets federal funds for research facility revamp

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 6
Volume 19
Issue 6

The Taussig Cancer Institute at the Cleveland Clinic has been awarded more than $2 million from the American Recovery and Reinvestment Act for the renovation and expansion of its translational cancer research facilities. The National Center for Research Resources, which is part of NIH, awarded the grant.


DEREK RAGHAVEN, MD, PHD

The Taussig Cancer Institute at the Cleveland Clinic has been awarded more than $2 million from the American Recovery and Reinvestment Act for the renovation and expansion of its translational cancer research facilities. The National Center for Research Resources, which is part of NIH, awarded the grant.

The funds will be used to update 3,600 square feet of laboratory space that was built on the clinic's main campus in 1928. The space was last renovated in the 1950s. Renovations will include a shared instrumentation room that will free up an additional 500 square feet to allow for more bench research.

The expanded laboratory area also will allow for the recruitment of up to four new independent researchers, a dozen technical support positions, and an administrative assistant.

"The expansion of our translational cancer research capabilities is essential to the mission of the Taussig Cancer Institute," said Derek Raghavan, MD, PhD, chair of the institute, in a written statement. "This award will allow us to continue to bring the latest research straight from the lab to the bedside to aid in the diagnosis and treatment of patients."

Recent Videos
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
4 experts in this video
2 experts are featured in this series.
4 experts in this video
Related Content